


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61M	A2	(11) International Publication Number: WO 00/18447 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/US99/20807 (22) International Filing Date: 13 September 1999 (13.09.99) (30) Priority Data: 09/164,642 29 September 1998 (29.09.98) US (71) Applicant: IMPAX PHARMACEUTICALS, INC. [US/US]; 30831 Huntwood Avenue, Hayward, CA 94544 (US). (72) Inventors: TING, Richard; 38 Woodranch Circle, Danville, CA 94506 (US). HSIAO, Charles; 2012 Westbrook Lane, Livermore, CA 94550 (US). (74) Agents: SCHWARTZ, Jeff et al.; 1801 K Street, NW, Suite 400K, Washington, DC 20006 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION  (57) Abstract A multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when compared to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored film coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages can provide a convenient and cost effective drug delivery unit, particularly for patients with a regimen of prescribed dosages that varies during their treatment period.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MULTIPLEX DRUG DELIVERY SYSTEM
SUITABLE FOR ORAL ADMINISTRATION

Field of the Invention

5 The present invention relates to a single drug delivery unit suitable for oral administration containing at least two distinct drug dosage packages. This multiplex system contains at least two immediate-release compartments substantially enveloped
10 by a scored extended-release compartment. The scored nature of the extended-release compartment facilitates the separation by the patient of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage. Upon separation, each individual drug dosage package can exhibit an
15 equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system. Accordingly, in a preferred embodiment, the separability of the multiplex drug delivery system enables its use throughout the entire course of a varying dosage regimen, and thus, facilitates cost effective patient compliance.

Background of the Invention

20 Drug efficacy depends upon the maintenance of the proper therapeutic levels of the drug over the required treatment period. With respect to orally administered drugs, the effectiveness of treatment depends, in part or sometimes in whole, on patient compliance with the prescribed dosage regimen. Particularly where the
25 prescribed dosage increases or decreases during the treatment period, patient compliance can suffer because of the unavailability of, or inconvenience in obtaining, the appropriate dosage of the prescribed medication at different times.

It would therefore be beneficial for patients to have one drug delivery unit that allows patients themselves to regulate the amount of drug to administer. Such a
30 capability would enable patients to use the same drug delivery unit throughout their entire treatment period even where their prescribed dosage changes during that time. Patients in such circumstances would have the convenience and cost effectiveness of

obtaining in one unit and at the same time the different dosages of their prescribed drug that would be needed during their treatment period.

A valuable contribution to the art therefore would be the development of a multiplex drug delivery system suitable for oral administration containing at least two
5 immediate-release compartments substantially enveloped by a scored extended-release compartment that facilitates the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release
10 profile for the active agent as compared to one another and to that of the entire multiplex system.

Summary of the Invention

Accordingly, an objective of the present invention is a single drug delivery unit suitable for oral administration that patients could separate into individual drug
15 dosage packages. These individual drug dosage packages can exhibit an equivalent, and preferably identical, release profile for the active agent when compared to one another or when compared to the entire, intact multiplex drug delivery system.

The present invention accomplishes this objective through a multiplex drug delivery system suitable for oral administration containing at least two immediate-release compartments. The scored extended-release compartment of the invention
20 allows the separation of the multiplex drug delivery system into individual drug dosage packages for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.

25 One preferred embodiment of the claimed invention is a multiplex drug delivery system suitable for oral administration comprising at least two immediate-release compartments substantially enveloped by a scored extended-release compartment. The extended-release compartment can comprise a combination of a hydrophilic and a hydrophobic material. In such an embodiment, the hydrophilic
30 polymer(s) dissolves away to weaken the extended-release compartment, while the hydrophobic material retards the water, thus helping to preserve the integrity of the drug delivery system. Where the immediate-release compartments are inert (*i.e.*, do not comprise an active agent), they can facilitate a bursting effect, which can disrupt any remaining integrity of the extended-release compartment.

In another preferred embodiment of the claimed invention, each immediate-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof and the scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with the combination of a hydrophilic polymer and a hydrophobic material.

In a further preferred embodiment, each immediate-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with a polymer. In one other preferred embodiment, the scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with the combination of a hydrophilic polymer and a hydrophobic material. By varying the composition of the polymer(s) in the immediate-release compartments and/or the relative composition of the hydrophilic polymer and hydrophobic material in the extended-release compartment, the respective time periods for the dissolution of the active agent or the bursting effect can be adjusted.

In a preferred embodiment of the claimed invention, the active agent contained in the multiplex drug delivery system can be a drug. In other embodiments, that drug can be a therapeutic or a prophylactic drug.

In one preferred embodiment of the claimed invention, the drug of the multiplex drug delivery system can be diltiazem, trapidil, urapidil, benzydaron, dipyridamole, isosorbide mononitrate, or lidoflazine. In another embodiment, the drug can be a non-steroidal antiinflammatory drug (NSAID) or steroidal antiinflammatory drug. In an embodiment, the steroidal antiinflammatory drug can be diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, or naproxen. In yet another embodiment, the drug can be acetaminophen, aldosterone, alprenolol, amitriptyline, aspirin, beclomethasone, dipropionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylinipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine, furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, imipramine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline,

isoproterenol sulfate, isosorbide dinitrate, levallorphan tartrate, levodopa, lidocaine HCl, lignocaine, lorcainide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methylpreonisolone, methyltestosterone mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, 5 naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepinephrine bitartrate, norethindrone, nortriptylene HCl, oxprenolol, oxyphenbutazone, penicillamine, pentazocine HCl, pentazocine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl, phenylephrine bitartrate, phenytoin, pindolal, prazosin, prednisone, progesterone, 10 propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicylamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, or verapamil HCl.

In one other preferred embodiment of the claimed invention, the active agent can preferably be isosorbide-5-mononitrate.

15 In a preferred embodiment, the active agent of the multiplex drug delivery system can exhibit the following *in vitro* dissolution profile when measured in a type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$ in deionized water at 75 rotations per minute:

from about 0% to about 90% of said active agent is released between 1 hour 20 and 16 hours of measurement in said apparatus; and

from about 0% to about 100% of said active agent is released between 1.5 hours and 28 hours after measurement in said apparatus.

In such a preferred embodiment, the active agent of the multiplex drug delivery system can be isosorbide-5-mononitrate.

25 In still another preferred embodiment, the active agent of the multiplex drug delivery system can exhibit the following *in vitro* dissolution profile when measured in a type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$ in deionized water at 75 rotations per minute:

from about 10% to about 75% of said active agent is released between 1 hour 30 and 5 hours of measurement in said apparatus; and

no less than about 90% of said active agent is released after 6 hours of measurement in said apparatus.

In one preferred embodiment of the claimed invention, the polymer of the multiplex drug delivery system can be alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, 5 pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, shellac, or zein, and preferably hydroxypropyl methylcellulose.

10 In yet another preferred embodiment, the hydrophilic polymer of the multiplex drug delivery system can be carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, or povidone, and preferably hydroxypropyl methylcellulose.

In a preferred embodiment of the claimed invention, the hydrophobic material of the multiplex drug delivery system can be carnauba wax, ethylcellulose, glyceryl 15 palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, or stearic acid, and preferably hydrogenated vegetable oil.

The present invention also accomplishes these and other objectives through a method for preparing a multiplex drug delivery system suitable for oral administration comprising the steps of: combining an effective amount of an active agent, or a 20 pharmaceutically acceptable salt thereof, and a polymer to form at least two immediate-release compartments; combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a hydrophilic polymer and a hydrophobic material to form an extended-release compartment; press coating the extended-release compartment to substantially envelop the at least two immediate- 25 release compartments, and scoring the extended-release compartment such that the immediate-release compartments are separable.

In a preferred embodiment, the method for preparing a multiplex drug delivery system suitable for oral administration can include combining by blending, perforated 30 pan coating, fluidized particle coating, wet granulation, fluid-bed granulation, or dry granulation according to methods recognized in the art.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. The detailed description and the specific examples, however, indicate only preferred embodiments of the invention.

Various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Description of Drawings

5 Figure 1 is a schematic of one preferred embodiment of the multiplex drug delivery system suitable for oral administration, which contains two immediate-release compartments substantially enveloped by a scored extended-release compartment. The scored extended-release compartment of the invention allows the separation of the multiplex drug delivery system into individual drug dosage packages
10 for oral administration of the prescribed dosage, each of which can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.

 In this preferred embodiment, the multiplex system consists of an oblong tablet scored in the middle to allow for easy breaking of the tablet. Each half of the
15 tablet contains an immediate-release compartment located concentrically within the round tablet edges, allowing for a slightly thicker wall from the center edge when the tablet is broken in half. The distance between immediate-release compartments need not be greater than twice the distance between the interface of the immediate-release and extended-release compartments and that of the extended-release compartment and
20 the outer surface or optional cosmetic compartment, so long as once separated, each individual drug dosage package can exhibit an equivalent, and preferably identical, release profile for the active agent as compared to one another and to that of the entire multiplex system.

 Figure 2 is a graph showing the *in vitro* dissolution profile (% dissolved versus
25 time) of isosorbide mononitrate extended release tablets (Lots 127-19A and 127-19B), according to an embodiment of the present invention, in deionized water using a type 2 dissolution apparatus (paddle method) at $37 \pm 0.5^\circ\text{C}$ at 75 rotations per minute (rpm). See U.S. Pharmacopeia XXII <711> Dissolution.

 Figure 3 is a graph showing the *in vitro* dissolution profiles (% dissolved
30 versus time) of an entire multiplex drug delivery system containing two immediate-release compartments (each comprising the active agent isosorbide mononitrate) (Lot 127-19A "whole tablet"), and an individual drug dosage package thereof after separation (Lot 127-19A "half tablet"), according to respective embodiments of the present invention, in deionized water using a type 2 dissolution apparatus (paddle

method) at $37 \pm 0.5^{\circ}\text{C}$ at 75 rotations per minute (rpm). *See* U.S. Pharmacopeia XXII <711> Dissolution.

Detailed Description of Preferred Embodiments

5 In accordance with the present invention, the term "active agent" includes one or more drugs, their pharmaceutically acceptable salts, pro-drug forms, metabolites, and derivatives.

 Active agents include therapeutic or prophylactic compounds as described in the Physicians' Desk Reference, most preferably including (but not limited to) those
10 prescribed for the prevention and/or treatment of angina and hypertension: diltiazem, trapidil, urapidil, benzydaron, dipyridamole, isosorbide mononitrate, and lidoflazine; and those prescribed for the prevention and/or treatment of rheumatic diseases such as rheumatoid arthritis: non-steroidal antiinflammatory drugs (NSAIDs) and steroidal antiinflammatory drugs such as diclofenac sodium, ibuprofen,
15 ketoprofen, diflunisal, piroxicam, motrin, and naproxen, and combinations thereof.

 The active agent of the present invention also preferably includes drugs that are subject to the first pass effect. Various examples of such drugs include (but are not limited to) acetaminophen, aldosterone, alprenolol, amitriptyline, aspirin, beclomethasone, dipropionate, bromocriptine, butorphanol tartrate, chlormethiazole,
20 chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylinipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine,
25 furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, imipramine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline, isoproterenol sulfate, isosorbide dinitrate, levallorphan tartrate, levodopa, lidocaine HCl, lignocaine, lorcinide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methylpreonisolone, methyltestosterone
30 mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepinephrine bitartrate, norethindrone, nortriptylene HCl, oxprenolol, oxyphenbutazone, penicillamine, pentazocine HCl, pentazocine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl,

phenylephrine bitartrate, phenytoin, pindolol, prazosin, prednisone, progesterone, propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicylamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, and verapamil HCl.

5 In a preferred embodiment of the present invention, the active agent may include the drug, isosorbide-5-mononitrate, an organic nitrate, which is a vasodilator with effects on both arteries and veins. The empirical formula is $C_6H_9NO_6$ and the molecular weight is 191.14. The chemical name for isosorbide mononitrate is 1,4:3,6-dianhydro-D-glucitol 5-nitrate.

10 Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate and most of the clinical activity of the dinitrate can be attributable to the mononitrate. A principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins is known to promote peripheral pooling of blood and
15 decrease venous return to the heart, thereby reducing left ventricular and diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains
20 undefined. The mechanism by which isosorbide mononitrate relieves angina pectoris is not fully understood.

Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. In humans, isosorbide mononitrate is not subject to first pass metabolism in the liver. The overall elimination half-life of isosorbide mononitrate is
25 about 6 hours. The rate of clearance is the same in healthy young adults, and in patients with various degrees of renal, hepatic, or cardiac dysfunction.

In accordance with the present invention, the term "polymer" includes single or multiple polymeric substances, which can swell, gel, degrade or erode on contact with an aqueous environment (*e.g.*, water), such as one or more of alginic acid,
30 carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl

methylcellulose, polymethacrylates, povidone, pregelatinized starch, shellac, and zein, and combinations thereof.

The "hydrophilic polymers" of the present invention include one or more of carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, 5 hydroxypropyl methylcellulose, methylcellulose, and povidone. The "hydrophobic materials" of the present invention include one or more of carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, and stearic acid.

Without further elaboration, it is believed that one skilled in the art, using the 10 preceding description, can practice the present invention to the fullest extent. The following examples are illustrative only, and not limiting of the remainder of the disclosure in any way whatsoever.

Examples

15 The method below was employed to obtain a multiplex drug delivery system, the composition of which is set forth in the tables immediately following in Table 1:

Immediate-Release Compartment. Isosorbide mononitrate was first mixed with silicon dioxide in a Patterson-Kelley V-blender together with microcrystalline cellulose, croscarmellulose sodium, and magnesium stearate for 15 minutes. The 20 powder blend was then compressed using a Manesty Dry-cota with a 3/16" diameter, round, flat-face punch and die set. The hardness of the tablets were maintained at 4 ± 2 kp.

Immediate-Release Compartment Plus Extended-Release Compartment
Isosorbide mononitrate was mixed with silicon dioxide in a Patterson-Kelley V- 25 blender together with hydroxypropyl methylcellulose 2208, microcrystalline cellulose, hydrogenated vegetable oil, and magnesium stearate for 15 minutes. The core tablets were press-coated using a Korsch Core Coater 5/16" x 3/4" capsule shape punches. The hardness of the tablets were maintained at 12 ± 4 kp.

In addition, the formulation of respective release compartments can occur by 30 appropriate granulation methods. In wet granulation, solutions of the binding agent (polymer) are added with stirring to the mixed powders. The powder mass is wetted with the binding solution until the mass has the consistency of damp snow or brown sugar. The wet granulated material is forced through a sieving device. Moist material

from the milling step is dried by placing it in a temperature controlled container. After drying, the granulated material is reduced in particle size by passing through a sieving device. Lubricant is added, and the final blend is then compressed.

In fluid-bed granulation, particles of inert material and/or active agent are suspended in a vertical column with a rising air stream. While the particles are suspended, the common granulating materials in solution are sprayed into the column. There is a gradual particle buildup under a controlled set of conditions resulting in tablet granulation. Following drying and the addition of lubricant, the granulated material is ready for compression.

In dry-granulation, the active agent, diluent, and lubricant are blended and compressed into large tablets. The compressed large tablets are comminuted through the desirable mesh screen by sieving equipment. Some more lubricant is added to the granulated material and blended gently. The material is then compressed into tablets.

15

TABLE 1

	QUANTITY/TABLET	
	Example #1	Example #2
Immediate-Release (IR) Compartment	Lot 127-13	Lot 127-13
Isosorbide-5-mononitrate 80% w/lactose	25.0 mg	25.0 mg
Croscarmellose sodium	1.1 mg	1.1 mg
Microcrystalline cellulose	28.2 mg	28.2 mg
Colloidal silicon dioxide	0.2 mg	0.2 mg
Magnesium stearate	0.5 mg	0.5 mg
Total:	55.0 mg	55.0 mg
IR Compartment Plus Extended-Release (ER) Compartment	Lot 127-19A	Lot 127-19B
IR Compartment (two cores)	110.0 mg	110.0 mg
Isosorbide-5-mononitrate 80% w/lactose	37.5 mg	37.5 mg
Hydroxypropyl methylcellulose, type 2208	201.6 mg	288.0 mg
Microcrystalline cellulose	245.5 mg	245.5 mg
Hydrogenated vegetable oil, type 1	223.2 mg	136.8 mg
Colloidal silicon dioxide	3.6 mg	3.6 mg
Magnesium stearate	7.2 mg	7.2 mg
Blue dye	1.4 mg	1.4 mg
Total:	830.0 mg	830.0 mg

The invention has been disclosed broadly and illustrated in reference to representative embodiments described above. Those skilled in the art will recognize that various modifications can be made to the present invention without departing from the spirit and scope thereof.

What is claimed is:

1. A multiplex drug delivery system suitable for oral administration comprising at least two immediate-release compartments substantially enveloped by a scored extended-release compartment, which facilitates separation of said multiplex drug delivery system into individual drug dosage packages.

2. The multiplex drug delivery system of claim 1, wherein each of said immediate-release compartments further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and wherein said scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with a combination of a hydrophilic polymer and a hydrophobic material, and wherein each of said individual drug dosage packages exhibits an equivalent release profile for said active agent when compared to one another or when compared to said multiplex drug delivery system in its entirety.

3. The multiplex drug delivery system of claim 1, wherein each of said immediate-release compartments further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with a polymer.

4. The multiplex drug delivery system of claim 1, wherein said scored extended-release compartment further comprises an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, in a compressed blend with a combination of a hydrophilic polymer and a hydrophobic material.

5. The multiplex drug delivery system of claim 2, wherein said active agent is a drug.

6. The multiplex drug delivery system of claim 5, wherein said drug is a therapeutic drug.

7. The multiplex drug delivery system of claim 5, wherein said drug is a prophylactic drug.

8. The multiplex drug delivery system of claim 5, wherein said drug is selected from the group consisting of diltiazem, trapidil, urapidil, benziodarone, dipyridamole, isosorbide mononitrate, and lidoflazine.

9. The multiplex drug delivery system of claim 5, wherein said drug is selected from the group consisting of non-steroidal antiinflammatory drugs (NSAIDs) and steroidal antiinflammatory drugs.

10. The multiplex drug delivery system of claim 9, wherein said steroidal antiinflammatory drug is selected from the group consisting of diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, and naproxen.

11. The multiplex drug delivery system of claim 5, wherein said drug is selected from the group consisting of acetaminophen, aldosterone, alprenolol, amitriptyline, aspirin, beclomethasone, dipropionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylinipramine, dextropropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine, furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, imipramine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline, isoproterenol sulfate, isosorbide dinitrate, levallorphan tartrate, levodopa, lidocaine HCl, lignocaine, lorcinide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methylpreonisolone, methyltestosterone mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepinephrine bitartrate, norethindrone, nortriptylene HCl, oxprenolol, oxyphenbutazone, penicillamine, pentazocine HCl, pentazocine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl, phenylephrine bitartrate, phenytoin, pindolol, prazosin, prednisone, progesterone, propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicylamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, and verapamil HCl.

12. The multiplex drug delivery system of claim 5, wherein said active agent is isosorbide-5-mononitrate.

13. The multiplex drug delivery system of claim 2, wherein said active agent exhibits the following *in vitro* dissolution profile when measured in a type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at 37°C ± 0.5°C in deionized water at 75 rotations per minute:

- (a) from about 0% to about 90% of said active agent is released between 1 hour and 16 hours of measurement in said apparatus; and
- (b) from about 0% to about 100% of said active agent is released between 1.5 hours and 28 hours after measurement in said apparatus.

14. The multiplex drug delivery system of claim 13, wherein said active agent exhibits the following *in vitro* dissolution profile when measured in a type 2 dissolution apparatus (paddle) according to U.S. Pharmacopeia XXII at $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$ in deionized water at 75 rotations per minute:

- (a) from about 10% to about 75% of said active agent is released between 1 hour and 5 hours of measurement in said apparatus; and
- (b) no less than about 90% of said active agent is released after 6 hours of measurement in said apparatus.

15. The multiplex drug delivery system of claim 14, wherein said active agent is isosorbide-5-mononitrate.

16. The multiplex drug delivery system of claim 3, wherein said polymer is selected from the group consisting of alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, shellac, and zein.

17. The multiplex drug delivery system of claim 16, wherein said polymer is selected from the group consisting of colloidal silicon dioxide, microcrystalline cellulose, and hydroxypropyl methylcellulose.

18. The multiplex drug delivery system of claim 2, wherein said hydrophilic polymer is selected from the group consisting of carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, and povidone.

19. The multiplex drug delivery system of claim 18, wherein said hydrophilic polymer is hydroxypropyl methylcellulose.

20. The multiplex drug delivery system of claim 2, wherein said hydrophobic material is selected from the group consisting of carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, and stearic acid.

21. The multiplex drug delivery system of claim 20, wherein said hydrophobic material is hydrogenated vegetable oil.
22. A method for preparing a multiplex drug delivery system suitable for oral administration comprising the steps of:
- (a) combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a polymer to form at least two immediate-release compartments;
 - (b) combining an effective amount of an active agent, or a pharmaceutically acceptable salt thereof, and a hydrophilic polymer and a hydrophobic material to form an extended-release compartment;
 - (c) press coating said extended-release compartment to substantially envelop said at least two immediate-release compartments, and
 - (d) scoring said extended-release compartment such that said immediate-release compartments are separable.
23. The method of claim 22, wherein said combining is selected from the group consisting of blending, perforated pan coating, fluidized particle coating, wet granulation, fluid-bed granulation, and dry granulation.
24. The method of claim 22, wherein said active agent is a drug.
25. The method of claim 24, wherein said drug is a therapeutic drug.
26. The method of claim 24, wherein said drug is a prophylactic drug.
27. The method of claim 24, wherein said drug is selected from the group consisting of diltiazem, trapidil, urapidil, benziodarone, dipyridamole, isosorbide mononitrate, and lidoflazine.
28. The method of claim 24, wherein said drug is selected from the group consisting of non-steroidal antiinflammatory drugs (NSAIDs) and steroidal antiinflammatory drugs.
29. The method of claim 28, wherein said steroidal antiinflammatory drug is selected from the group consisting of diclofenac sodium, ibuprofen, ketoprofen, diflunisal, piroxicam, motrin, and naproxen.
30. The method of claim 24, wherein said drug is selected from the group consisting of acetaminophen, aldosterone, alprenolol, amitriptyline, aspirin, beclomethasone, dipropionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylinipramine, dextropropoxyphene,

dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21-deoxyuridine, furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, imipramine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline, isoproterenol sulfate, isosorbide dinitrate, levallorphan tartrate, levodopa, lidocaine HCl, lignocaine, lorcaïnide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methylpreonisolone, methyltestosterone mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepinephrine bitartrate, norethindrone, nortriptylene HCl, oxprenolol, oxyphenbutazone, penicillamine, pentazocine HCl, pentazocine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl, phenylephrine bitartrate, phenytoin, pindolal, prazosin, prednisone, progesterone, propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicylamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, and verapamil HCl.

31. The method of claim 24, wherein said active agent is isosorbide-5-mononitrate.

32. The method of claim 24, wherein said polymer is selected from the group consisting of alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, cellulose, pregelatinized starch, sodium alginate, starch, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polymethacrylates, povidone, shellac, and zein.

33. The method of claim 32, wherein said polymer is selected from the group consisting of colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, and hydroxypropyl methylcellulose.

34. The method of claim 24, wherein said hydrophilic polymer is selected from the group consisting of carboxymethylcellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, and povidone.

35. The method of claim 34, wherein said hydrophilic polymer is hydroxypropyl methylcellulose.

36. The method of claim 24, wherein said hydrophobic material is selected from the group consisting of carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylates, and stearic acid.

37. The method of claim 36, wherein said hydrophobic material is hydrogenated vegetable oil.

1/3




FIG. 1

2/3




FIG. 2




FIG. 3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 April 2000 (06.04.2000)

PCT

(10) International Publication Number
WO 2000/018447 A3

(51) International Patent Classification⁷: A61K 9/20, 9/44

(21) International Application Number:
PCT/US1999/020807

(22) International Filing Date:
13 September 1999 (13.09.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/164,642 29 September 1998 (29.09.1998) US

(71) Applicant: IMPAX PHARMACEUTICALS, INC.
[US/US]; 30831 Huntwood Avenue, Hayward, CA 94544
(US).

(72) Inventors: TING, Richard; 38 Woodranch Circle,
Danville, CA 94506 (US). HSIAO, Charles; 2012 West-
brook Lane, Livermore, CA 94550 (US).

(74) Agents: SCHWARTZ, Jeff et al.; McKenna & Cuneo,
L.L.P., 1900 K Street, NW, Washington, DC 20006 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
UZ, VN, YU, ZA, ZW.



(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
19 February 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION



(57) Abstract: A multiple drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when compared to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored film coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages can provide a convenient and cost effective drug delivery unit, particularly for patients with a regimen of prescribed dosages that varies during their treatment period (Figure 1).

WO 2000/018447 A3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/20807

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/20, 9/44

US CL :424/ 464, 467, 468, 469, 470, 473

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/ 464, 467, 468, 469, 470, 473

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, MEDLINE, DRUGU, TOXLIT, EMBASE

search terms: tablet, dosage form, sustained release, delayed release, scored, perforated

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	FR 2,585,948 A1 (P. F. MEDICAMENT) 13 February 1987, see abstract.	1-6, 16-19, 22-27, 32-35 1-37

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*& document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 NOVEMBER 1999

Date of mailing of the international search report

29 NOV 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN K. SEIDLECK

Telephone No. (703) 308-1235